COPD Flashcards
In COPD airflow limitation is due to a combination of (?) (obstructive bronchiolitis) and parenchymal destruction (emphysema)
small airways disease
In COPD airflow limitation is due to a combination of small airways disease ((?)) and parenchymal destruction (emphysema)
obstructive bronchiolitis
In COPD airflow limitation is due to a combination of small airways disease (obstructive bronchiolitis) and (?) (emphysema)
parenchymal destruction
In COPD airflow limitation is due to a combination of small airways disease (obstructive bronchiolitis) and parenchymal destruction ((?))
emphysema
What are 5 complications of COPD?
Cor pulmonale Depression Anxiety Type 2 respiratory failure Secondary polycythaemia
What is the aim of COPD treatment?
To reduce symptoms and exacerbations and improve quality of life
COPD patients with excessive (?) should be taught active cycle of breathing techniques, and how to use positive expiratory pressure devices by a physiotherapist.
sputum production
COPD patients with excessive sputum production should be taught (?), and how to use positive expiratory pressure devices by a physiotherapist.
active cycle of breathing techniques
COPD patients with excessive sputum production should be taught active cycle of breathing techniques, and how to use (?) devices by a physiotherapist.
positive expiratory pressure
All COPD patients should be offered which two vaccines?
Pneumococcal vaccine
Annual influenza vaccine
In COPD patients, (?) treatment should be considered for patients with distressing or disabling breathlessness despite maximal use of inhalers, and continued if an improvement is seen in symptoms, ability to undertake activities of daily living, exercise capacity, or lung function.
nebulised
In COPD patients, nebulised treatment should be considered for patients with distressing or disabling breathlessness despite (?), and continued if an improvement is seen in symptoms, ability to undertake activities of daily living, exercise capacity, or lung function.
maximal use of inhalers
In COPD patients, nebulised treatment should be considered for patients with (?) despite maximal use of inhalers, and continued if an improvement is seen in symptoms, ability to undertake activities of daily living, exercise capacity, or lung function.
distressing or disabling breathlessness
What initial empirical inhaler treatment should be given to COPD patients?
A short-acting bronchodilator as required to relieve breathlessness and exercise limitation
Can be SABA or SAMA
A patient with COPD is currently being treated with a SABA as required but needs a step-up in management. They DO NOT have asthmatic features. What is the most appropriate next step in management?
LABA + LAMA
In patients who continue to be breathless or have exacerbations, offer a long-acting beta2 agonist (LABA) and a long-acting muscarinic antagonist (LAMA).
In the treatment of COPD, discontinue SAMA treatment if a (?) is given.
LAMA
Treatment with a SABA as required may be continued in all stages of COPD
In the treatment of COPD, discontinue (?) treatment if a LAMA is given.
SAMA
Treatment with a SABA as required may be continued in all stages of COPD
If a patient with COPD being treated with a LAMA and LABA has a severe exacerbation requiring hospitalisation, what should you consider adding to their management?
Inhaled corticosteroid (ICS)
If an ICS is given, review at least annually and document the reason for continuation.
If a patient with COPD being treated with a LAMA and LABA has at least two moderate exacerbations (requiring systemic corticosteroids and/or antibacterial treatment) within a year, what should you consider adding to their management?
Inhaled corticosteroid (ICS)
If an ICS is given, review at least annually and document the reason for continuation.
In patients on a LAMA and LABA whose day-to-day symptoms continue to adversely impact their quality of life, consider trialling the addition of an (?) for 3 months.
Inhaled corticosteroid (ICS)
If symptoms have improved, continue triple therapy and review at least annually. If there has been no improvement, step back down to a LAMA and LABA combination.
In patients on a LAMA and LABA whose day-to-day symptoms continue to adversely impact their quality of life, consider trialling the addition of an ICS for (?) months.
3 months
If symptoms have improved, continue triple therapy and review at least annually. If there has been no improvement, step back down to a LAMA and LABA combination.
A patient with COPD is currently being treated with a SABA as required but needs a step-up in management. They DO have asthmatic features. What is the most appropriate next step in management?
LABA + ICS
If an ICS is given, review annually documenting the reason for continuation.
If a patient with COPD being treated with a LABA and ICS has a severe exacerbation requiring hospitalisation, what should you add to their management?
LAMA
Discontinue SAMA treatment if a LAMA is given. Treatment with a SABA as required may be continued in all stages of COPD.
If a patient with COPD being treated with a LABA and ICS has at least two moderate exacerbations requiring systemic corticosteroids and/or antibacterial treatment within a year, what should you add to their management?
LAMA
Discontinue SAMA treatment if a LAMA is given. Treatment with a SABA as required may be continued in all stages of COPD.
If a patient with COPD being treated with a LABA and ICS continues to have day-to-day symptoms adversely impacting their quality of life, what should you add to their management?
LAMA
Discontinue SAMA treatment if a LAMA is given. Treatment with a SABA as required may be continued in all stages of COPD.
In the management of COPD, which antibiotic can you consider giving as prophylaxis to reduce the risk of exacerbations?
Azithromycin [unlicensed]
Review treatment after the first 3 months, then at least 6 monthly thereafter; only continue if benefits outweigh risks.